Tony Berberabe

Olaparib/radium-223 demonstrated superior rPFS outcomes compared with radium-223 alone in patients with castration-resistant prostate cancer.

Adjuvant atezolizumab plus mFOLFOX6 improved disease-free survival vs mFOLFOX6 alone in patients with stage III, mismatch repair–deficient colon cancer.

Axatilimab displayed similar efficacy regardless of the number of prior lines of therapy in chronic graft-versus-host disease.

All patients with relapsed/refractory multiple myeloma experienced a response when treated with anitocabtagene autoleucel in a phase 1 trial.

Adjuvant pembrolizumab generated a DFS benefit vs observation in patients with high-risk muscle-invasive bladder cancer after radical surgery.

Treatment with elacestrant led to a clinically meaningful improvement in progression-free-survival compared with standard-of-care therapy among patients with estrogen receptor–positive/HER2-negative, ESR1-mutated advanced or metastatic breast cancer.

Patients with primary advanced or recurrent endometrial cancer whose disease was deficient mismatch repair/microsatellite instability-high, TP53 mutated, or had no specific molecular profile, experienced a survival benefit when treated with dostarlimab-gxly plus chemotherapy vs placebo plus chemotherapy.

First-line treatment with itolizumab produced rapid, durable responses and favorable safety in patients with acute graft-vs-host disease.

Patients with clear cell renal cell carcinoma who received the combination of pembrolizumab and axitinib over sunitinib showed a benefit in adjusted overall survival and type and timing of subsequent therapy in a second interim analysis of the phase 3 KEYNOTE-426 study.

Single-agent pemigatinib is being compared with gemcitabine plus cisplatin in patients with unresectable and/or metastatic cholangiocarcinoma whose tumor harbor FGFR2 fusions or rearrangements in the ongoing, phase 3 FIGHT-302 trial.

Talquetamab, when delivered at the recommended phase 2 dose of 405 µg/kg weekly, induced a high clinical response rate with favorable tolerabilty in patients with relapsed/refractory multiple myeloma.

December 9, 2020 - Whole breast irradiation, following breast-conserving surgery and adjuvant endocrine therapy, can be omitted from the treatment journey of low-risk, older patients with pT1-2 tumors (≥3 cm) who are on local control at 10 years.

Interim data from a phase 2 study indicate that neoadjuvant hormone therapy may reduce tumor volume in men with high-risk prostate cancer planning to undergo radical prostatectomy.

Compelling evidence has been presented about the various checkpoint inhibitors in bladder cancer, but, additionally there have been some provocative papers looking at genomic sequencing of upper tract compared with bladder that shows certain differences